TRAVERE THERAPEUTICS, INC. Debt Securities, Available-for-sale
TRAVERE THERAPEUTICS, INC. (TVTX) had Debt Securities, Available-for-sale of $371.44 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale $371.44M.
- 2026-03-31: Debt Securities, Available-for-sale $186.31M.
- 2025-12-31: Debt Securities, Available-for-sale $229.76M.
- 2025-09-30: Debt Securities, Available-for-sale $143.60M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $371.44M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $186.31M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $229.76M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $143.60M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $244.38M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $260.35M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $312.17M 10-K · filed 2026-02-19 |
| 2024-09-30 | $241.03M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $293.11M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $397.79M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $508.68M 10-K · filed 2025-02-21 |
| 2023-09-30 | $490.40M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $420.46M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $400.14M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $388.56M 10-K · filed 2024-02-20 |
| 2022-09-30 | $354.99M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $373.41M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $346.82M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $387.13M 10-K · filed 2023-02-23 |
| 2021-09-30 | $400.86M 10-Q · filed 2021-10-29 |
| 2021-06-30 | $439.50M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $372.64M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $276.82M 10-K · filed 2022-02-24 |
| 2020-09-30 | $255.79M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $220.21M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $289.44M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $336.09M 10-K · filed 2021-03-01 |
| 2019-09-30 | $341.83M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $350.24M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $377.81M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $368.67M 10-K · filed 2020-02-24 |
| 2018-09-30 | $323.99M 10-Q · filed 2018-11-01 |
| 2017-12-31 | $201.24M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |